Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Isis is a biopharmaceutical company focused on the discovery and development of antisense drugs and the Ibis T5000 biosensor system. The company operates two primary segments: Drug Discovery and Development, and the Ibis Division. As of the reporting date, the company had one approved commercial product (Vitravene) and 15 drugs in various stages of development.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Total Revenue | $9,334 | $18,034 |
| Net Loss Applicable to Common Stock | $(19,652) | $(49,317) |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.86) |
| Cash and Cash Equivalents (End of Period) | $105,359 | $7,988 |
| Short-term Investments | $32,581 | $43,504 |
| Total Debt (Long-term + Current Portion) | $143,915 | $147,750 |
| Working Capital | $127,993 | $82,065 |
Note: Cash and cash equivalents include $64.4 million held by Symphony GenIsis, Inc., a variable interest entity consolidated in Q2 2006.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 48% year-over-year (from $18.0M to $9.3M). This was driven primarily by a significant drop in research and development revenue from collaborative agreements ($17.6M to $8.8M), attributed to reduced activity with partner Eli Lilly and the completion of a drug sale to OncoGenex in the prior year.
- Improved Net Loss: Net loss applicable to common stock improved significantly (decreased by 60%) to $19.7M from $49.3M. This improvement was largely due to a $13.6 million benefit recognized from the consolidation of Symphony GenIsis, Inc., which offset operating losses.
- Liquidity Surge: Cash and cash equivalents increased from $8.0M to $105.4M. This increase is primarily due to the consolidation of Symphony GenIsis's cash balance ($64.4M) and proceeds from the sale of Alnylam equity securities ($4.4M).
- Operating Expenses: Total operating expenses decreased 22% to $42.5M from $54.5M, driven by cost savings from 2005 restructuring activities and a reduction in restructuring charges ($7.9M decrease).
- Investment Gains: The company recorded a net gain on investments of $2.3M, compared to zero in the prior period, resulting from the sale of Alnylam securities offset by an impairment loss on an investment in Antisense Therapeutics Ltd.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Capital Resources: Management believes current resources are sufficient to meet anticipated requirements through at least the end of 2008.
- Symphony GenIsis: The company expects the benefit from the non-controlling interest in Symphony GenIsis to be lower in the remaining quarters of 2006 due to one-time items in Q2. However, as development expenditures increase in 2007, the benefit to net loss is expected to increase.
- Product Pipeline: Positive Phase 1 and Phase 2 results were reported for ISIS 301012 (cholesterol) and ISIS 113715 (diabetes). The company plans to continue advancing these programs and commercializing the Ibis T5000 biosensor system.
- Financing: In May 2006, the company entered an equity line of credit with Azimuth Opportunity Ltd. to purchase up to $75 million of common stock. The first drawdown of $5 million was completed in July 2006.
Risks and Contingencies
- Profitability: The company has incurred accumulated losses of approximately $790.5 million since inception and expects to incur additional operating losses in the future.
- Government Contract Reliance: Approximately 55% of revenue in the first half of 2006 was derived from U.S. government agencies. These contracts can be terminated at the government's convenience.
- Intellectual Property: The company faces risks regarding the protection of its patent portfolio and potential litigation, including an ongoing arbitration with Ajinomoto Co., Inc., for which a $600,000 liability has been recorded.
- Development Risks: Success depends on clinical trial results and regulatory approvals. Failure in trials (e.g., past failures of Affinitak and alicaforsen) could materially harm the business.
Investor Verification Checklist
- Symphony GenIsis Consolidation: Verify the sustainability of the $13.6M non-controlling interest benefit and the terms of the option to reacquire the intellectual property (32% compounded annual return).
- Revenue Concentration: Assess the risk associated with 55% of revenue coming from U.S. government contracts and the potential for termination.
- Cash Burn Rate: Confirm the runway of $137.9M in liquid assets against the projected operating expenses and debt obligations ($143.9M total debt).
- Legal Contingencies: Monitor the finalization of the Ajinomoto arbitration settlement and any potential additional liabilities.
- Stock-Based Compensation: Review the impact of the new SFAS 123(R) adoption on future operating expenses ($7.5M unrecognized cost remaining).